1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.

Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists

Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists

  1. ThirdEyeFloond
    Bioorganic & Medicinal Chemistry Letters
    Volume 18, Issue 7, 1 April 2008, Pages 2385-2389

    Suk Youn Kang, Sung-Han Lee, Hee Jeong Seo, Myung Eun Jung, Kwangwoo Ahn, Jeongmin Kim and Jinhwa Lee


    Cannabinoid CB1 receptors have been the focus of extensive studies since the first clinical results of rimonabant (SR141716) for the treatment of obesity and related metabolic disorders were reported in 2001. To further evaluate the properties of CB receptors, we have designed a new series of tetrazole-biarylpyrazoles. The various analogues were efficiently prepared and bio-assayed for binding to cannabinoid CB1 receptor. Six of the new compounds which displayed high in vitro CB1 binding affinities were assayed for binding to CB2 receptor. Noticeably, cyclopentyl-tetrazole (9a) demonstrated good binding affinity and selectivity for CB1 receptor (IC50 = 11.6 nM and CB2/CB1 = 366).